You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification Name GSK716155 Accession Number DB05162 Type Small Molecule Groups Investigational Description GSK716155 (formerly Albugon), a novel long-acting form of glucagon-like peptide-1 (GLP-1), is in clinical trials for the treatment of Type 2 diabetes. It was created using Human Genome Sciences' proprietary albuminfusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein.
Structure Synonyms Not Available External Identifiers Not Available Approved Prescription Products Not Available Approved Generic Prescription Products Not Available Approved Over the Counter Products Not Available Unapproved/Other Products Not Available International Brands Not Available Brand mixtures Not Available Salts Not Available Categories Not Available UNII 5E7U48495E CAS number 782500-75-8 Weight Not Available Chemical Formula Not Available InChI Key Not Available InChI Not Available IUPAC Name Not Available SMILES Not Available Pharmacology Indication Investigated for use/treatment in diabetes mellitus type 2. Structured Indications Not Available Clinical Trials Pharmacodynamics Not Available Mechanism of action GSK716155, a GLP-1 receptor agonist, has been shown to have multiple physiologic activities in the central nervous system and gastrointestinal system that could lower A1C. It increases peripheral glucose uptake, enhances insulin secretion, decreases glucagon secretion, delays gastric emptying, reduces food intake and induces satiety at CNS.
Target Kind Pharmacological action Actions Organism UniProt ID Glucagon-like peptide 1 receptor Protein unknown Not Available Human P43220 details Related Articles Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half life Not Available Clearance Not Available Toxicity Not Available Affected organisms Not Available Pathways Not Available SNP Mediated Effects Not Available SNP Mediated Adverse Drug Reactions Not Available Interactions Drug Interactions Not Available Food Interactions Not Available References Synthesis Reference Not Available General References Not Available External Links Not Available ATC Codes Not Available AHFS Codes Not Available PDB Entries Not Available FDA label Not Available MSDS Not Available ADMET Predicted ADMET features Not Available Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Not Available Spectra Mass Spec (NIST) Not Available Spectra Taxonomy Classification Not classified Targets
comments powered by Disqus. comments powered by
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24